DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Chidamide is an investigational drug.
There have been 54 clinical trials for Chidamide. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2019.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, and Lymphoma, T-Cell, Peripheral. The leading clinical trial sponsors are Chipscreen Biosciences, Ltd., Sichuan University, and Sun Yat-sen University.
There are three US patents protecting this investigational drug and twenty-six international patents.
Recent Clinical Trials for Chidamide
|Biomarker Guided Treatment in DLBCL||Ruijin Hospital||Phase 2|
|A Single-arm, Open, Phase II Study of Chidamide Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma||Sun Yat-sen University||Phase 2|
|Chidamide and R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma||Sun Yat-sen University||Phase 2|
Top disease conditions for Chidamide
Top clinical trial sponsors for Chidamide
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Chidamide||Start Trial||Histone deacetylase inhibitors||Orchid Chemicals & Pharmaceuticals Limited (Chennai, IN)||Start Trial|
|Chidamide||Start Trial||Crystal form of chidamide, preparation method and use thereof||SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (Shenzhen, Guangdong, CN)||Start Trial|
|Chidamide||Start Trial||Agents for killing HIV-1-infected cells and application thereof||KAGOSHIMA UNIVERSITY (Kogoshima-Shi, Kagoshima, JP)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Chidamide||European Patent Office||2205563||1989-12-31||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|